Scinai Immunotherapeutics (SCNI) Invested Capital (2019 - 2026)

Scinai Immunotherapeutics has reported Invested Capital for 8 years, with the latest figure at $354000.0 in Q1 2026.

• Quarterly Invested Capital changed N/A year-over-year to $354000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 2.43% YoY) and the FY2025 annual result came in at $329000.0, down 22.41% from the prior year.
• Invested Capital grew to $354000.0 in Q1 2026 per SCNI's latest filing, from $329000.0 in the prior quarter.
• Over five years, Invested Capital peaked at $1.8 million in Q1 2022 and troughed at $329000.0 in Q4 2025.
• A 5-year average of $637214.3 and a median of $390500.0 in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital slumped 99.97% in 2022, then surged 36.54% in 2025.
• Over 5 years, Invested Capital stood at $382000.0 in 2022, then increased by 3.66% to $396000.0 in 2023, then increased by 7.07% to $424000.0 in 2024, then slipped by 22.41% to $329000.0 in 2025, then increased by 7.6% to $354000.0 in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $354000.0, $329000.0, and $497000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.